Stockscreener 앱 받기
1.03
0.96%
-0.01
시간 외 거래:
1.04
0.01
+0.97%
전일 마감가:
$1.04
열려 있는:
$1.07
하루 거래량:
177.94K
Relative Volume:
0.11
시가총액:
$5.46M
수익:
-
순이익/손실:
$-17.06M
주가수익비율:
-0.0146
EPS:
-70.7173
순현금흐름:
$-14.18M
1주 성능:
+3.00%
1개월 성능:
-9.65%
6개월 성능:
-80.75%
1년 성능:
-99.59%
1일 변동 폭
$1.00
$1.07
1주일 범위
$0.9596
$1.08
52주 변동 폭
$0.7715
$414.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
CNSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
1.03 | 5.46M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.15 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.60 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.00 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.97 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit - Barchart.com
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit - citybuzz -
CNSP: Insights on TPI 287's Promise at Brain Tumor Summit | CNSP Stock News - GuruFocus
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | CNSP Stock News - GuruFocus
Brain Cancer Breakthrough: New Drug Achieves 12 Responses in Glioblastoma Patients, FDA Grants Special Status - Stock Titan
CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shift to TPI-287 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail
CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved By Stocktwits - Investing.com India
CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus
CNSP Secures Funding to Support Operations Through 2026 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan
CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail
CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Canada
CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - The Globe and Mail
Jazz Pharma. v. Avadel CNS Pharma: Federal Circuit Applies a Fact-Specific Approach to the Patent Infringement Safe Harbor - JD Supra
CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull
CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan
CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com
CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus
CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Stock Titan
Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360
Fed. Circ. Asks What Law Applies For Sleep Drug Injunction - Law360
Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNSP stock touches 52-week low at $0.99 amid sharp decline - Investing.com
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace
Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance
CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.99%
4.71%
자본화:
|
볼륨(24시간):